Blincyto (blinatumomab) And Benzyl Alcohol Toxicity For Pediatric Patients
BLINCYTO Recall Summary BLINCYTO (blinatumomab), a cancer medication, is being recalled in Canada because it contains benzyl alcohol, which can cause serious toxicity in pediatric patients. The recall affects the drug supply across Canada. Pediatric patients who have received or are scheduled to receive this medication may be at risk.
- Reason
- Product safety
- Category
- drug recall
- Country
- Canada
- Agency
- HC-DRUGS
- Recall date
- 2018-06-12
- Status
- Ongoing
- Distribution
- Canada-wide
Official recall notice from HC-DRUGS
Recall details on Nibble Recalls: https://trynibble.app/recalls/fd832655-4059-4f57-bc83-7c427290eba0